Epidemiology of prostate cancer.

Prostate cancer incidence and mortality rates vary worldwide. In the United States, prostate cancer is the most common malignancy affecting men and is the second-leading cause of cancer death. Risk of developing prostate cancer is associated with advancing age, African American ethnicity, and a positive family history, and may be influenced by diet and other factors. The incidence of prostate cancer increased sharply after the introduction of widespread screening for prostate-specific antigen (PSA), although rates have now returned to levels seen before that time. PSA screening has been associated with a shift toward diagnosis of earlier-stage disease, but this has not been accompanied by a shift toward a lower histologic grade. Although overall prostate cancer mortality rates decreased during the 1990s, it was largely because of reductions in deaths among men diagnosed with distant disease. In contrast, mortality rates for men diagnosed with localized or regional disease increased gradually during most of the 1990s before decreasing slightly among white men and reaching plateaus among African Americans.

[1]  W. Satariano,et al.  Cause of death in men diagnosed with prostate carcinoma , 1998, Cancer.

[2]  E. Rimm,et al.  A prospective study of dietary fat and risk of prostate cancer. , 1993, Journal of the National Cancer Institute.

[3]  E. Giovannucci,et al.  Tomato products, lycopene, and prostate cancer risk. , 2002, The Urologic clinics of North America.

[4]  D A Meyers,et al.  Major Susceptibility Locus for Prostate Cancer on Chromosome 1 Suggested by a Genome-Wide Search , 1996, Science.

[5]  J. Moul,et al.  Epidemiology of radical prostatectomy for localized prostate cancer in the era of prostate-specific antigen: an overview of the Department of Defense Center for Prostate Disease Research national database. , 2002, Surgery.

[6]  Laurence R. Paquette,et al.  Improved prostate cancer-specific survival and other disease parameters: impact of prostate-specific antigen testing. , 2002, Urology.

[7]  D. Grignon,et al.  Prostate cancer stage shift has eliminated the gap in disease-free survival in black and white American men after radical prostatectomy. , 2002, The Journal of urology.

[8]  B. Levin,et al.  American Cancer Society Guidelines for the Early Detection of Cancer , 2002, CA: a cancer journal for clinicians.

[9]  M. Pike,et al.  Association of mis-sense substitution in SRD5A2 gene with prostate cancer in African-American and Hispanic men in Los Angeles, USA , 1999, The Lancet.

[10]  Steven Shea,et al.  Diabetes Mellitus and the Risk of Prostate Cancer , 2002, Cancer investigation.

[11]  Taylor Murray,et al.  Cancer statistics, 2000 , 2000, CA: a cancer journal for clinicians.

[12]  Meir J. Stampfer,et al.  Plasma Insulin-Like Growth Factor-I and Prostate Cancer Risk: A Prospective Study , 1998 .

[13]  M. Grønbæk,et al.  Does amount or type of alcohol influence the risk of prostate cancer? , 2002, The Prostate.

[14]  M. Terris,et al.  Vasectomy and prostate cancer characteristics of patients referred for prostate biopsy. , 2002, The Journal of urology.

[15]  B. Lunenfeld The ageing male: demographics and challenges , 2002, World Journal of Urology.

[16]  G. Haas,et al.  Epidemiology of prostate cancer , 1997, CA: a cancer journal for clinicians.

[17]  E. Riboli,et al.  Plasma insulin-like growth factor-I, insulin-like growth factor-binding proteins, and prostate cancer risk: a prospective study. , 2000, Journal of the National Cancer Institute.

[18]  Henrik Grönberg,et al.  Prostate cancer epidemiology , 2003, The Lancet.

[19]  P. Bunting,et al.  Screening for prostate cancer with prostate-specific antigen: beware the biases. , 2002, Clinica chimica acta; international journal of clinical chemistry.

[20]  Michael J Thun,et al.  Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. , 2003, The New England journal of medicine.

[21]  P. Babb,et al.  Patterns and trends in prostate cancer incidence, survival, prevalence and mortality. Part I: international comparisons , 2002, BJU international.

[22]  P. Babb,et al.  Patterns and trends in prostate cancer incidence, survival, prevalence and mortality. Part II: individual countries , 2002, BJU international.

[23]  A. Coldman,et al.  Trends in prostate cancer incidence and mortality: an analysis of mortality change by screening intensity. , 2003, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

[24]  B. Lunenfeld,et al.  The ageing male , 2001, World Journal of Urology.

[25]  J. Xu Combined analysis of hereditary prostate cancer linkage to 1q24-25: results from 772 hereditary prostate cancer families from the International Consortium for Prostate Cancer Genetics. , 2000, American journal of human genetics.

[26]  F. Collins,et al.  Early age at diagnosis in families providing evidence of linkage to the hereditary prostate cancer locus (HPC1) on chromosome 1. , 1997, Cancer research.

[27]  S. Schwartz,et al.  Incidence of adenocarcinoma of the prostate in Asian immigrants to the United States and their descendants. , 1999, The Journal of urology.

[28]  C Coley,et al.  Prostate-specific antigen best practice policy--part I: early detection and diagnosis of prostate cancer. , 2001, Urology.

[29]  R. Hayes,et al.  Serum selenium and risk of prostate cancer in U.S. blacks and whites , 2003, International journal of cancer.

[30]  H. Adami,et al.  Reduced risk of prostate cancer among patients with diabetes mellitus , 2002, International journal of cancer.

[31]  E. Metter,et al.  Serum levels of insulin-like growth factor I (IGF-I), IGF-II, IGF-binding protein-3, and prostate-specific antigen as predictors of clinical prostate cancer. , 2000, The Journal of clinical endocrinology and metabolism.

[32]  K. Imaida,et al.  Diet and prostate cancer. , 2002, Toxicology.

[33]  D. Kiel,et al.  Bone mass and the risk of prostate cancer: the Framingham Study. , 2002, The American journal of medicine.

[34]  D. English,et al.  Early growth, adult body size and prostate cancer risk , 2003, International journal of cancer.

[35]  A. Hsing Hormones and prostate cancer: what's next? , 2001, Epidemiologic reviews.

[36]  E. Rimm,et al.  A prospective study of tomato products, lycopene, and prostate cancer risk. , 2002, Journal of the National Cancer Institute.

[37]  Robert A. Smith,et al.  American Cancer Society Guidelines for the Early Detection of Cancer, 2003 , 2003, CA: a cancer journal for clinicians.

[38]  T H Beaty,et al.  Family history and the risk of prostate cancer , 1990, The Prostate.

[39]  L. Clegg,et al.  Cancer survival among US whites and minorities: a SEER (Surveillance, Epidemiology, and End Results) Program population-based study. , 2002, Archives of internal medicine.

[40]  D. Sir Dairy products, calcium, and prostate cancer risk in the Physicians' Health Study , 2002 .

[41]  R. Vieth Dairy products, calcium, and prostate cancer risk in the Physicians' Health Study. , 2002, The American journal of clinical nutrition.

[42]  O. Bratt Hereditary prostate cancer: clinical aspects. , 2002, The Journal of urology.

[43]  W. Catalona,et al.  Screening for prostate cancer in high risk populations. , 2002, The Journal of urology.

[44]  P. Laake,et al.  Dietary fat intake and risk of prostate cancer: A prospective study of 25,708 Norwegian men , 1997, International journal of cancer.

[45]  A. Polednak Black-white differences in tumor grade (aggressiveness) at diagnosis of prostate cancer, 1992-1998. , 2002, Ethnicity & disease.

[46]  A. Whittemore,et al.  Prostate cancer in relation to diet, physical activity, and body size in blacks, whites, and Asians in the United States and Canada. , 1995, Journal of the National Cancer Institute.

[47]  R. Tarone,et al.  Trends in prostate cancer mortality among black men and white men in the United States , 2003, Cancer.

[48]  B. Turnbull,et al.  Decreased incidence of prostate cancer with selenium supplementation: results of a double-blind cancer prevention trial. , 1998, British journal of urology.

[49]  A. Sarma,et al.  Prostate cancer incidence, mortality, and survival trends in the United States: 1981-2001. , 2002, Seminars in urologic oncology.

[50]  S. Piantadosi,et al.  Clinical evidence for and implications of the multistep development of prostate cancer. , 1990, The Journal of urology.

[51]  J. Hanley,et al.  Competing risk analysis of men aged 55 to 74 years at diagnosis managed conservatively for clinically localized prostate cancer. , 1999, JAMA.

[52]  R. Souhami,et al.  Clinical Oncology, 2nd edn , 2000, British Journal of Cancer.

[53]  J. Moul,et al.  Prostate cancer in men age 50 years or younger: a review of the Department of Defense Center for Prostate Disease Research multicenter prostate cancer database. , 2000, The Journal of urology.

[54]  O. Bratt Hereditary prostate cancer , 2000, BJU international.

[55]  Perspective: prostate cancer susceptibility genes. , 2002, Endocrinology.

[56]  T. Beaty,et al.  Mendelian inheritance of familial prostate cancer. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[57]  B. Henderson,et al.  Cancers of the prostate and breast among Japanese and white immigrants in Los Angeles County. , 1991, British Journal of Cancer.